Back to School: How biopharma can reboot drug development. Access exclusive analysis here

QLT buying Atrix

QLT (TSE:QLT; QLTI) will buy ATRX for about $751 million in cash and stock, net of ATRX's $104.1 million in cash. Prior to the deal announcement, ATRX's Thursday market cap was

Read the full 315 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE